Eli Lilly Withdraws COVID-19 Treatments from EMA Review
EMA has ended rolling review of bamlanivimab and etesevimab COVID-19 antibody treatments after Eli Lilly Netherlands BV withdraws from the review process.
The European Medicines Agency announced on Nov. 2, 2021 that it was stopping its rolling review of bamlanivimab and etesevimab COVID-19 antibody treatments after Eli Lilly Netherlands BV decided to remove the treatments from the review process. EMA’s Committee for Medicinal Products for Human Use (CHMP) had been reviewing data on the two products as part of the rolling review since March 2021. According to EMA, there were questions about the quality of the treatments.
In a letter from Lilly to EMA, the company stated that “CHMP has determined that prospective concurrent validation is required for submission of a formal marketing authorisation application. Given the current demand from EU member states, Lilly forecasts that no additional/new drug substance manufacturing campaigns will be needed for the foreseeable future. Therefore, at this point Lilly is not in a position to generate the additional data required by the CHMP to progress to a formal marketing authorization application.”
EMA stated in a press release that Lilly may request another rolling review or submit an application for market authorization in the future. “The withdrawal has no consequences on the previous advice issued in March and patients may continue to receive the medicines based on national arrangements,” the agency stated in the release.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
